ASX listed PharmAust has received a $400,000 rebate from the Federal Government in recognition of their cutting edge research and development program being undertaken at two of the Perth-based company’s wholly owned subsidiaries. Pharmaust’s new anti-cancer drug, Monepantel, has been powering though human and K9 trials with considerable success.
31/01/2017 - 06:08
Pharmaust banks $400k rebate from Feds after successful anti cancer trials
By Matt Birney
31/01/2017 - 06:08
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX